ACA
ANAB icon

Apis Capital Advisors’s AnaptysBio ANAB Stock Holding History

Apis Capital Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5M Buy
497,000
+259,000
+109% +$15.7M 3.27% 10
2026
Q1 		$13.2M Buy
+238,000
New +$12.8M 2.04% 19

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Apis Capital Advisors's ANAB Position: Q2 2026 in Review

Apis Capital Advisors increased its AnaptysBio (ANAB) stake by 109% in Q2 2026, buying an estimated $15.7M and bringing the position to 497,000 shares worth $33.5M. The position accounts for 3.27% of the portfolio, ranked #10.

Apis Capital Advisors first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Apis Capital Advisors held 497,000 shares of AnaptysBio worth $33.5M as of Q2 2026.
  • Apis Capital Advisors bought 259,000 AnaptysBio shares in Q2 2026, an estimated $15.7M.
  • AnaptysBio made up 3.27% of Apis Capital Advisors's portfolio in Q2 2026, its #10 holding.
  • Apis Capital Advisors first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Apis Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.